Pharmaceuticals
News Category
VERAXA Biotech AG’s Antibody Platform Positioned for Value Creation Amid Strong Sector Deal Activity
The article highlights how VERAXA Biotech AG, with its next-generation antibody platform, is poised to benefit from the sustained high level of strate...
Ace Therapeutics Unveils Comprehensive Preclinical Pain Research Platform for Analgesic Drug Development
Ace Therapeutics announces a full-spectrum preclinical analgesic drug development service with diverse in vivo pain models and integrated research cap...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve profitability, affecting 32 employees, as ...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial on Track
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, with its lead candidate HLP003 for major depressiv...
Oncotelic Therapeutics Highlighted in NetworkNewsAudio for Innovative Drug Pipeline and CEO's Track Record
Oncotelic Therapeutics is featured in a NetworkNewsAudio release emphasizing its innovative therapeutics pipeline and the leadership of CEO Dr. Vuong ...
ABVC BioPharma Receives US$70,000 Licensing Payment from ForSeeCon for Vitargus, Totaling US$566,000
ABVC BioPharma received a US$70,000 licensing payment from ForSeeCon for its biodegradable vitreous substitute Vitargus, bringing cumulative payments ...
Nutriband to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference
Nutriband Inc. will showcase its lead product, an abuse-deterrent fentanyl patch, at the upcoming Noble Capital Markets conference, highlighting its p...
TransCode Therapeutics Acquires Polynoma and Secures $25M Investment to Advance Phase 2 Trial of TTX-MC138
TransCode Therapeutics acquires Polynoma and secures $25M from CK Life Sciences to fund its lead microRNA candidate through a Phase 2 trial, creating ...
Annovis Bio Raises $3.4 Million in Registered Direct Offering to Support Alzheimer’s and Parkinson’s Programs
Annovis Bio announced a $3.4 million registered direct offering led by H.C. Wainwright, with proceeds allocated for working capital and general corpor...
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution Agreement with Phalanx for Mexican Market Expansion
Voyageur Pharmaceuticals has entered a non-exclusive distribution and wholesale agreement with Phalanx to register and distribute its barium contrast ...
ABVC BioPharma Receives Additional $100,000 Licensing Payment from OncoX, Highlighting the Value of Its Asset-Light Licensing Model
ABVC BioPharma's receipt of a fifth licensing payment from OncoX in 2025, totaling $695,950, underscores the execution of its licensing-driven busines...
Thomas Meier to Succeed Matthias Gaertner as CEO of Medios AG
Medios AG appoints Thomas Meier as new CEO effective February 1, 2026, aiming to leverage his experience in capital-efficient growth to drive the comp...
Soligenix Reports Q3 2025 Results, Highlights Progress in CTCL and Psoriasis Trials
Soligenix (NASDAQ: SNGX) reported third quarter 2025 financial results and provided updates on key clinical milestones, including upcoming Phase 2a da...
Voyageur Pharmaceuticals Appoints Virginia Alling to Board of Directors to Accelerate U.S. Market Expansion
Voyageur Pharmaceuticals strengthens its board with seasoned financial executive Virginia Alling, alongside recent appointments, to drive U.S. capital...
Redcare Pharmacy Appoints Hendrik Krampe as New CFO
Redcare Pharmacy's Supervisory Board has designated Hendrik Krampe as CFO, effective December 1, 2025, succeeding Jasper Eenhorst, bringing extensive ...
NanoViricides Secures $6 Million in Registered Direct Offering to Advance Antiviral Drug Development
NanoViricides announced a $6 million registered direct offering with a healthcare institutional investor, proceeds of which will fund working capital ...
TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer to Advance Oncology Pipeline
TransCode Therapeutics has appointed Dr. Michel Janicot as Senior Development Officer, bringing over 35 years of oncology drug-development experience ...
CTT Pharma CEO to Issue Letter to Shareholders on Strategic Initiatives
CTT Pharmaceutical Holdings announces its CEO will release a letter on December 2, 2025, detailing advancements in SEC reporting, funding, manufacturi...
Creative Bioarray Launches In Vitro Metabolism Assay Kits to Streamline Drug Development
Creative Bioarray's new in vitro metabolism assay kits leverage CYP450 and UGT enzyme systems to enhance drug testing accuracy and efficiency, address...
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
South Fork Instruments Launches Kemtrak UV Spectra for Real-Time Deep-UV Measurement in Bioprocessing
South Fork Instruments introduces the Kemtrak UV Spectra Process Analyzer, a multi-wavelength deep-UV photometer enabling real-time absorbance measure...
Antisense Oligonucleotides Gain Momentum with Six FDA Approvals in Two Years, Reshaping Drug Development Economics
Antisense oligonucleotides (ASOs) are achieving higher approval rates and faster development timelines than traditional small molecules, with six new ...
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Telomir Pharmaceuticals announced positive safety data from IND-enabling studies for Telomir-1, with no adverse toxicities, supporting its advancement...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, ...
Tonix Pharmaceuticals Advances TNX-4800 for Lyme Disease Prophylaxis, Plans FDA Meeting in 2026
Tonix Pharmaceuticals provided an update on TNX-4800, a long-acting monoclonal antibody for seasonal Lyme disease prevention, with plans for FDA discu...
Voyageur Pharmaceuticals Acquires Iodine Extraction Technology and Appoints Dr. Brian Mueller as Director of Chemistry
Voyageur Pharmaceuticals secures exclusive ownership of a proprietary iodine extraction technology, the Mueller Process, and appoints its inventor Dr....
LIXTE Biotechnology Engages IBN to Enhance Corporate Communications Strategy
LIXTE Biotechnology Holdings Inc. has hired IBN to boost awareness of its cancer therapy pipeline through a broad distribution network, potentially in...
Lixte Biotechnology to Present at DealFlow Discovery Conference, Advancing Cancer Therapy Development
Lixte Biotechnology Holdings announced its participation in the DealFlow Discovery Conference, where it will highlight progress of its lead cancer dru...
Protheragen Delivers Comprehensive Drug Analysis Solutions Integrating Stability, Impurity, and Chemical-Physical Testing
Protheragen's integrated drug analysis services, including stability studies, impurity testing, and chemical-physical tests, support pharmaceutical de...
Creative Biolabs Upgrades Biosimilar Development and CDMO Platform to Enhance Physicochemical and Biological Characterization
Creative Biolabs announces an upgrade to its end-to-end biosimilar development and CDMO platform, expanding capabilities in physicochemical characteri...
Quantumzyme Corp. Reports 2025 Progress and Sets 2026 Strategic Goals, Including AI Integration and Name Change
Quantumzyme Corp. outlines its 2025 achievements in enzyme R&D and AI integration, and announces a proposed name change to Quantum Genesis AI Corp. as...
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
BioVaxys announced positive Phase 2 results for MVP-S combined with pembrolizumab and low-dose cyclophosphamide in metastatic bladder cancer, showing ...
Helus Pharma Reports Positive Phase 2a SPL026 Data Published in Nature Medicine
Helus Pharma announced that its Phase 2a trial of SPL026 for major depressive disorder showed significant symptom reduction and was published in Natur...
Oncotelic Therapeutics Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Oncotelic Therapeutics is highlighted in a BioMedWire editorial examining how biotech M&A is increasingly targeting late-stage, de-risked assets, posi...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Iodine and Barium Contrast Media Manufacturing Facility
Voyageur Pharmaceuticals is analyzing three potential U.S. locations for its vertically integrated contrast media plant, aiming to secure the best inc...
Quoin's NETHERTON NOW Campaign Surpasses 2 Million Video Views, Amplifying Awareness of Netherton Syndrome
Quoin Pharmaceuticals' NETHERTON NOW campaign has generated 2 million video views and 24 million impressions, highlighting the growing global awarenes...
Soligenix Secures EMA Positive Opinion for Dusquetide in Behçet's Disease, Unlocking European Development Incentives
Soligenix receives positive EMA opinion for orphan drug designation of dusquetide in Behçet's disease, providing market exclusivity and development in...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects with Strategic Feasibility Studies
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects, completing bankable feasibility studies t...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates Stephen Fry, former Eli Lilly executive, to its Board, aiming to enhance performance culture and organizational transformation, with e...
LIXTE Biotechnology's LB-100: The Only Clinical-Stage PP2A Inhibitor Poised to Transform Cancer Treatment
LIXTE Biotechnology holds the world's only clinical-stage PP2A inhibitor, LB-100, which enhances sensitivity to immunotherapy and chemotherapy while d...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Detailing Transformational Year of Clinical and Strategic Progress
LIXTE Biotechnology Holdings filed its 2025 Form 10-K, highlighting a year of leadership changes, clinical advancement of LB-100, the acquisition of L...
PolyPeptide Shareholders Approve All Board Proposals at 2026 Annual General Meeting
The shareholders of PolyPeptide Group AG approved all board proposals, including re-election of directors and auditors, at the company's fifth annual ...
Soligenix Showcased for Platform-Based Drug Development Strategy
Soligenix leverages its synthetic hypericin platform across multiple dermatologic indications, demonstrating how platform technology can streamline dr...
LIXTE Biotechnology’s LB-100 Poised to Transform Cancer Treatment by Enhancing Existing Therapies
LIXTE Biotechnology’s first-in-class PP2A inhibitor LB-100 is advancing through clinical trials for solid tumors with high unmet need, offering a nove...
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
Lantern Pharma's expansion of its predictBBB platform into a Large Quantitative Model enhances drug discovery by providing real-time, web-based molecu...
Earth Science Tech Inc. (ETST) Strengthens Position in Telemedicine and Pharmacy Ecosystem
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy platform, emphasizing ...
Tonix Pharmaceuticals to Present at Two Major Investor Conferences in May
Tonix Pharmaceuticals will showcase its commercial and pipeline progress at the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual V...
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides reported progress in its quarterly filing, highlighting regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug desi...